Gilead Makes Virology Bet with MYR Buy

By Michelle Liu

Pharma Deals Review: Vol 2020 Issue 12 (Table of Contents)

Published: 15 Dec-2020

DOI: 10.3833/pdr.v2020.i12.2578     ISSN: 1756-7874

Section: Mergers & Acquisitions



Gilead Sciences has agreed to acquire MYR Pharmaceuticals, a German biotechnology company focused on the development and commercialisation of therapeutics for the treatment of chronic hepatitis delta virus (HDV)...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details